STERIS (NYSE:STE – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 9.050-9.250 for the period, compared to the consensus earnings per share estimate of 9.160. The company issued revenue guidance of $5.5 billion-$5.5 billion, compared to the consensus revenue estimate of $5.5 billion. STERIS also updated its FY25 guidance to $9.05-$9.25 EPS.
STERIS Stock Up 1.7 %
NYSE:STE traded up $3.69 on Friday, hitting $219.19. The stock had a trading volume of 1,071,783 shares, compared to its average volume of 490,598. STERIS has a 1 year low of $195.47 and a 1 year high of $248.24. The firm’s fifty day simple moving average is $232.29 and its two-hundred day simple moving average is $227.64. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. The stock has a market cap of $21.62 billion, a P/E ratio of 50.03 and a beta of 0.85.
STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.03. STERIS had a return on equity of 13.91% and a net margin of 8.02%. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the business posted $2.03 earnings per share. STERIS’s revenue was up 7.3% on a year-over-year basis. Analysts predict that STERIS will post 9.02 earnings per share for the current year.
STERIS Announces Dividend
Analyst Ratings Changes
STE has been the topic of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Stephens reissued an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday. KeyCorp raised their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.00.
View Our Latest Stock Report on STE
Insider Activity
In related news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.14% of the stock is owned by corporate insiders.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 11/4 – 11/8
- What Are Dividend Champions? How to Invest in the Champions
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.